Loading…
Product Society LLC, a drug manufacturer in North Hollywood, California, failed to comply with Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, resulting in adulterated OTC drug products for topical and oral use. The company did not adequately test incoming components such as glycerin for identity and safety specifications, particularly failing to perform required limit testing for hazardous contaminants like Diethylene Glycol (DEG) and Ethylene Glycol (EG) before using them in manufacturing. Additionally, the firm relied on supplier certificates of analysis without establishing and validating the reliability of each supplier's testing at appropriate intervals, as required by 21 CFR 211.84(d). The FDA conducted an inspection from November 18-27, 2024, and issued this warning letter on May 8, 2025, following the company's December response to the inspection findings.